FIELD: biotechnology.
SUBSTANCE: disclosed is a method of producing an ex vivo cell population containing antigen-specific T-cells for use in treating human cancer. Method involves induction of T-cells with peptides containing an epitope sequence from a library of epitope sequences.
EFFECT: each epitope sequence in the library corresponds to a protein encoded by the HLA allele, and binds to a protein encoded by the HLA allele of the subject, is immunogenic according to immunogenic analysis, is presented by antigen-presenting cells according to mass-spectrometric analysis and stimulates cytotoxicity of T-cells according to cytotoxicity analysis.
41 cl, 54 dwg, 25 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEOANTIGENS AND THEIR USE | 2019 |
|
RU2813924C2 |
| COMPOSITIONS AND METHODS FOR IMMUNE ONCOLOGY | 2016 |
|
RU2771624C2 |
| PEPTIDE OBTAINED FROM GPC3, PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING CANCER USING IT, IMMUNITY INDUCER AND METHOD FOR PRODUCING ANTIGEN-PRESENTING CELLS | 2016 |
|
RU2714117C2 |
| ANTI-PRE-S1 HBV ANTIBODIES | 2016 |
|
RU2739955C2 |
| IMMUNODOMINANT PROTEINS AND FRAGMENTS IN MULTIPLE SCLEROSIS | 2019 |
|
RU2828590C2 |
| ANTIBODIES BINDING CTLA-4 AND APPLICATION THEREOF | 2018 |
|
RU2756100C1 |
| SPECIFIC ANTIBODIES TO PD-L1 AND METHODS FOR THEIR APPLICATION | 2017 |
|
RU2749109C2 |
| ARTIFICIAL ANTIGEN-PRESENTING CELLS AND METHODS FOR THEIR APPLICATION | 2018 |
|
RU2763798C1 |
| T-CELL RECEPTORS RECOGNIZING R175H OR Y220C MUTATION IN p53 | 2020 |
|
RU2830061C2 |
| NEOANTIGENS AND THEIR APPLICATION | 2019 |
|
RU2805196C2 |
